Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 NK211 (nogitecan, topotecan) plus cisplatin in cervical cancer
jRCT2080221794Phase 1
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- May 2012
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK211 and cisplatin in Cervical Cancer (CC), sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
NK211cisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080221794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221794.